Recombinant  ||| S:0 E:12 ||| JJ
activated  ||| S:12 E:22 ||| JJ
protein  ||| S:22 E:30 ||| NN
C  ||| S:30 E:32 ||| NNP
treatment  ||| S:32 E:42 ||| NN
improves  ||| S:42 E:51 ||| VBZ
tissue  ||| S:51 E:58 ||| NN
perfusion  ||| S:58 E:68 ||| NNS
and  ||| S:68 E:72 ||| CC
oxygenation  ||| S:72 E:84 ||| NN
in  ||| S:84 E:87 ||| IN
septic  ||| S:87 E:94 ||| JJ
patients  ||| S:94 E:103 ||| NNS
measured  ||| S:103 E:112 ||| VBN
by  ||| S:112 E:115 ||| IN
near-infrared  ||| S:115 E:129 ||| JJ
spectroscopy  ||| S:129 E:142 ||| NNS
The  ||| S:142 E:146 ||| DT
purpose  ||| S:146 E:154 ||| NN
was  ||| S:154 E:158 ||| VBD
to  ||| S:158 E:161 ||| TO
test  ||| S:161 E:166 ||| VB
the  ||| S:166 E:170 ||| DT
hypothesis  ||| S:170 E:181 ||| NN
that  ||| S:181 E:186 ||| IN
muscle  ||| S:186 E:193 ||| NN
perfusion ||| S:193 E:202 ||| NN
,  ||| S:202 E:204 ||| ,
oxygenation ||| S:204 E:215 ||| NN
,  ||| S:215 E:217 ||| ,
and  ||| S:217 E:221 ||| CC
microvascular  ||| S:221 E:235 ||| JJ
reactivity  ||| S:235 E:246 ||| NN
would  ||| S:246 E:252 ||| MD
improve  ||| S:252 E:260 ||| VB
in  ||| S:260 E:263 ||| IN
patients  ||| S:263 E:272 ||| NNS
with  ||| S:272 E:277 ||| IN
severe  ||| S:277 E:284 ||| JJ
sepsis  ||| S:284 E:291 ||| NN
or  ||| S:291 E:294 ||| CC
septic  ||| S:294 E:301 ||| JJ
shock  ||| S:301 E:307 ||| NN
during  ||| S:307 E:314 ||| IN
treatment  ||| S:314 E:324 ||| NN
with  ||| S:324 E:329 ||| IN
recombinant  ||| S:329 E:341 ||| JJ
activated  ||| S:341 E:351 ||| JJ
protein  ||| S:351 E:359 ||| NN
C  ||| S:359 E:361 ||| NNP
( ||| S:361 E:362 ||| -LRB-
rh-aPC ||| S:362 E:368 ||| NNP
)  ||| S:368 E:370 ||| -RRB-
( ||| S:370 E:371 ||| -LRB-
n  ||| S:371 E:373 ||| CD
=  ||| S:373 E:375 ||| SYM
11 ||| S:375 E:377 ||| CD
)  ||| S:377 E:379 ||| -RRB-
and  ||| S:379 E:383 ||| CC
to  ||| S:383 E:386 ||| TO
explore  ||| S:386 E:394 ||| VB
whether  ||| S:394 E:402 ||| IN
these  ||| S:402 E:408 ||| DT
parameters  ||| S:408 E:419 ||| NNS
are  ||| S:419 E:423 ||| VBP
related  ||| S:423 E:431 ||| VBN
to  ||| S:431 E:434 ||| TO
macrohemodynamic  ||| S:434 E:451 ||| VB
indices ||| S:451 E:458 ||| NNS
,  ||| S:458 E:460 ||| ,
metabolic  ||| S:460 E:470 ||| JJ
status  ||| S:470 E:477 ||| NN
or  ||| S:477 E:480 ||| CC
Sequential  ||| S:480 E:491 ||| NNP
Organ  ||| S:491 E:497 ||| NNP
Failure  ||| S:497 E:505 ||| NNP
Assessment  ||| S:505 E:516 ||| NNP
( ||| S:516 E:517 ||| -LRB-
SOFA ||| S:517 E:521 ||| NNP
)  ||| S:521 E:523 ||| -RRB-
score ||| S:523 E:528 ||| NN
.  ||| S:528 E:530 ||| .
Patients  ||| S:530 E:539 ||| NNS
with  ||| S:539 E:544 ||| IN
contraindications  ||| S:544 E:562 ||| VBG
to  ||| S:562 E:565 ||| TO
rh-aPC  ||| S:565 E:572 ||| NNP
were  ||| S:572 E:577 ||| VBD
used  ||| S:577 E:582 ||| VBN
as  ||| S:582 E:585 ||| IN
a  ||| S:585 E:587 ||| DT
control  ||| S:587 E:595 ||| NN
group  ||| S:595 E:601 ||| NN
( ||| S:601 E:602 ||| -LRB-
n  ||| S:602 E:604 ||| CD
=  ||| S:604 E:606 ||| SYM
5 ||| S:606 E:607 ||| CD
) ||| S:607 E:608 ||| -RRB-
.  ||| S:608 E:610 ||| .
Patients  ||| S:610 E:619 ||| NNS
were  ||| S:619 E:624 ||| VBD
sedated ||| S:624 E:631 ||| CD
,  ||| S:631 E:633 ||| ,
intubated ||| S:633 E:642 ||| NN
,  ||| S:642 E:644 ||| ,
mechanically  ||| S:644 E:657 ||| RB
ventilated ||| S:657 E:667 ||| VBN
,  ||| S:667 E:669 ||| ,
and  ||| S:669 E:673 ||| CC
hemodynamically  ||| S:673 E:689 ||| VB
monitored  ||| S:689 E:699 ||| VBN
with  ||| S:699 E:704 ||| IN
the  ||| S:704 E:708 ||| DT
PiCCO  ||| S:708 E:714 ||| JJ
system ||| S:714 E:720 ||| NN
.  ||| S:720 E:722 ||| .
Tissue  ||| S:722 E:729 ||| NN
oxygen  ||| S:729 E:736 ||| NN
saturation  ||| S:736 E:747 ||| NNS
( ||| S:747 E:748 ||| -LRB-
StO2 ||| S:748 E:752 ||| NNP
)  ||| S:752 E:754 ||| -RRB-
was  ||| S:754 E:758 ||| VBD
measured  ||| S:758 E:767 ||| VBN
using  ||| S:767 E:773 ||| VBG
near-infrared  ||| S:773 E:787 ||| JJ
spectroscopy  ||| S:787 E:800 ||| NNS
( ||| S:800 E:801 ||| -LRB-
NIRS ||| S:801 E:805 ||| NNP
)  ||| S:805 E:807 ||| -RRB-
during  ||| S:807 E:814 ||| IN
the  ||| S:814 E:818 ||| DT
vascular  ||| S:818 E:827 ||| JJ
occlusion  ||| S:827 E:837 ||| JJ
test  ||| S:837 E:842 ||| NN
( ||| S:842 E:843 ||| -LRB-
VOT ||| S:843 E:846 ||| NNP
) ||| S:846 E:847 ||| -RRB-
.  ||| S:847 E:849 ||| .
Baseline  ||| S:849 E:858 ||| NNP
StO2  ||| S:858 E:863 ||| NNP
( ||| S:863 E:864 ||| -LRB-
StO2  ||| S:864 E:869 ||| NNP
baseline ||| S:869 E:877 ||| NN
) ||| S:877 E:878 ||| -RRB-
,  ||| S:878 E:880 ||| ,
rate  ||| S:880 E:885 ||| NN
of  ||| S:885 E:888 ||| IN
decrease  ||| S:888 E:897 ||| NN
in  ||| S:897 E:900 ||| IN
StO2  ||| S:900 E:905 ||| CD
during  ||| S:905 E:912 ||| IN
VOT  ||| S:912 E:916 ||| NNP
( ||| S:916 E:917 ||| -LRB-
StO2  ||| S:917 E:922 ||| FW
downslope ||| S:922 E:931 ||| FW
) ||| S:931 E:932 ||| -RRB-
,  ||| S:932 E:934 ||| ,
and  ||| S:934 E:938 ||| CC
rate  ||| S:938 E:943 ||| NN
of  ||| S:943 E:946 ||| IN
increase  ||| S:946 E:955 ||| NN
in  ||| S:955 E:958 ||| IN
StO2  ||| S:958 E:963 ||| CD
during  ||| S:963 E:970 ||| IN
the  ||| S:970 E:974 ||| DT
reperfusion  ||| S:974 E:986 ||| JJ
phase  ||| S:986 E:992 ||| NN
were  ||| S:992 E:997 ||| VBD
( ||| S:997 E:998 ||| -LRB-
StO2  ||| S:998 E:1003 ||| FW
upslope ||| S:1003 E:1010 ||| FW
)  ||| S:1010 E:1012 ||| -RRB-
determined ||| S:1012 E:1022 ||| VBN
.  ||| S:1022 E:1024 ||| .
Data  ||| S:1024 E:1029 ||| NNP
were  ||| S:1029 E:1034 ||| VBD
collected  ||| S:1034 E:1044 ||| VBN
before  ||| S:1044 E:1051 ||| IN
( ||| S:1051 E:1052 ||| -LRB-
T0 ||| S:1052 E:1054 ||| NNP
) ||| S:1054 E:1055 ||| -RRB-
,  ||| S:1055 E:1057 ||| ,
during  ||| S:1057 E:1064 ||| IN
( ||| S:1064 E:1065 ||| -LRB-
24  ||| S:1065 E:1068 ||| CD
hours  ||| S:1068 E:1074 ||| NNS
( ||| S:1074 E:1075 ||| -LRB-
T1a ||| S:1075 E:1078 ||| NNP
) ||| S:1078 E:1079 ||| -RRB-
,  ||| S:1079 E:1081 ||| ,
48  ||| S:1081 E:1084 ||| CD
hours  ||| S:1084 E:1090 ||| NNS
( ||| S:1090 E:1091 ||| -LRB-
T1b ||| S:1091 E:1094 ||| NNP
) ||| S:1094 E:1095 ||| -RRB-
,  ||| S:1095 E:1097 ||| ,
72  ||| S:1097 E:1100 ||| CD
hours  ||| S:1100 E:1106 ||| NNS
( ||| S:1106 E:1107 ||| -LRB-
T1c ||| S:1107 E:1110 ||| NNP
)  ||| S:1110 E:1112 ||| -RRB-
and  ||| S:1112 E:1116 ||| CC
96  ||| S:1116 E:1119 ||| CD
hours  ||| S:1119 E:1125 ||| NNS
( ||| S:1125 E:1126 ||| -LRB-
T1d ||| S:1126 E:1129 ||| NNP
) ||| S:1129 E:1130 ||| -RRB-
)  ||| S:1130 E:1132 ||| -RRB-
and  ||| S:1132 E:1136 ||| CC
6  ||| S:1136 E:1138 ||| CD
hours  ||| S:1138 E:1144 ||| NNS
after  ||| S:1144 E:1150 ||| IN
stopping  ||| S:1150 E:1159 ||| VBG
rh-aPC  ||| S:1159 E:1166 ||| JJ
treatment  ||| S:1166 E:1176 ||| NN
( ||| S:1176 E:1177 ||| -LRB-
T2 ||| S:1177 E:1179 ||| NNP
)  ||| S:1179 E:1181 ||| -RRB-
and  ||| S:1181 E:1185 ||| CC
at  ||| S:1185 E:1188 ||| IN
the  ||| S:1188 E:1192 ||| DT
same  ||| S:1192 E:1197 ||| JJ
times  ||| S:1197 E:1203 ||| NNS
in  ||| S:1203 E:1206 ||| IN
the  ||| S:1206 E:1210 ||| DT
controls ||| S:1210 E:1218 ||| NNS
.  ||| S:1218 E:1220 ||| .
At  ||| S:1220 E:1223 ||| IN
every  ||| S:1223 E:1229 ||| DT
assessment ||| S:1229 E:1239 ||| NN
,  ||| S:1239 E:1241 ||| ,
hemodynamic  ||| S:1241 E:1253 ||| NN
and  ||| S:1253 E:1257 ||| CC
metabolic  ||| S:1257 E:1267 ||| JJ
parameters  ||| S:1267 E:1278 ||| NNS
were  ||| S:1278 E:1283 ||| VBD
registered  ||| S:1283 E:1294 ||| VBN
and  ||| S:1294 E:1298 ||| CC
the  ||| S:1298 E:1302 ||| DT
SOFA  ||| S:1302 E:1307 ||| NNP
score  ||| S:1307 E:1313 ||| VBP
calculated ||| S:1313 E:1323 ||| VBN
.  ||| S:1323 E:1325 ||| .
The  ||| S:1325 E:1329 ||| DT
mean  ||| S:1329 E:1334 ||| JJ
+ ||| S:1334 E:1335 ||| CD
/ ||| S:1335 E:1336 ||| CD
-  ||| S:1336 E:1338 ||| :
standard  ||| S:1338 E:1347 ||| JJ
deviation  ||| S:1347 E:1357 ||| NN
Acute  ||| S:1357 E:1363 ||| NNP
Physiology  ||| S:1363 E:1374 ||| NNP
and  ||| S:1374 E:1378 ||| CC
Chronic  ||| S:1378 E:1386 ||| NNP
Health  ||| S:1386 E:1393 ||| NNP
Evaluation  ||| S:1393 E:1404 ||| NNP
II  ||| S:1404 E:1407 ||| NNP
score  ||| S:1407 E:1413 ||| NN
was  ||| S:1413 E:1417 ||| VBD
26.3  ||| S:1417 E:1422 ||| CD
+ ||| S:1422 E:1423 ||| CD
/ ||| S:1423 E:1424 ||| CD
-  ||| S:1424 E:1426 ||| :
6.6  ||| S:1426 E:1430 ||| CD
and  ||| S:1430 E:1434 ||| CC
28.6  ||| S:1434 E:1439 ||| CD
+ ||| S:1439 E:1440 ||| CD
/ ||| S:1440 E:1441 ||| CD
-  ||| S:1441 E:1443 ||| :
5.3  ||| S:1443 E:1447 ||| CD
in  ||| S:1447 E:1450 ||| IN
rh-aPC  ||| S:1450 E:1457 ||| JJ
and  ||| S:1457 E:1461 ||| CC
control  ||| S:1461 E:1469 ||| NN
groups ||| S:1469 E:1475 ||| NNS
,  ||| S:1475 E:1477 ||| ,
respectively ||| S:1477 E:1489 ||| RB
.  ||| S:1489 E:1491 ||| .
There  ||| S:1491 E:1497 ||| EX
were  ||| S:1497 E:1502 ||| VBD
no  ||| S:1502 E:1505 ||| DT
significant  ||| S:1505 E:1517 ||| JJ
differences  ||| S:1517 E:1529 ||| NNS
in  ||| S:1529 E:1532 ||| IN
macrohemodynamic  ||| S:1532 E:1549 ||| JJ
parameters  ||| S:1549 E:1560 ||| NNS
between  ||| S:1560 E:1568 ||| IN
the  ||| S:1568 E:1572 ||| DT
groups  ||| S:1572 E:1579 ||| NNS
at  ||| S:1579 E:1582 ||| IN
all  ||| S:1582 E:1586 ||| PDT
the  ||| S:1586 E:1590 ||| DT
time  ||| S:1590 E:1595 ||| NN
points ||| S:1595 E:1601 ||| NNS
.  ||| S:1601 E:1603 ||| .
In  ||| S:1603 E:1606 ||| IN
the  ||| S:1606 E:1610 ||| DT
rh-aPC  ||| S:1610 E:1617 ||| JJ
group ||| S:1617 E:1622 ||| NN
,  ||| S:1622 E:1624 ||| ,
base  ||| S:1624 E:1629 ||| NN
excess  ||| S:1629 E:1636 ||| NN
was  ||| S:1636 E:1640 ||| VBD
corrected  ||| S:1640 E:1650 ||| VBN
( ||| S:1650 E:1651 ||| -LRB-
P  ||| S:1651 E:1653 ||| NNP
< ||| S:1653 E:1655 ||| SYM
0.01 ||| S:1655 E:1659 ||| CD
)  ||| S:1659 E:1661 ||| -RRB-
from  ||| S:1661 E:1666 ||| IN
T1a  ||| S:1666 E:1670 ||| CD
until  ||| S:1670 E:1676 ||| IN
T2 ||| S:1676 E:1678 ||| NNP
,  ||| S:1678 E:1680 ||| ,
and  ||| S:1680 E:1684 ||| CC
blood  ||| S:1684 E:1690 ||| NN
lactate  ||| S:1690 E:1698 ||| NNS
was  ||| S:1698 E:1702 ||| VBD
significantly  ||| S:1702 E:1716 ||| RB
decreased  ||| S:1716 E:1726 ||| VBN
at  ||| S:1726 E:1729 ||| IN
T1d  ||| S:1729 E:1733 ||| NNP
and  ||| S:1733 E:1737 ||| CC
T2  ||| S:1737 E:1740 ||| NNP
( ||| S:1740 E:1741 ||| -LRB-
2.8  ||| S:1741 E:1745 ||| CD
+ ||| S:1745 E:1746 ||| CD
/ ||| S:1746 E:1747 ||| CD
-  ||| S:1747 E:1749 ||| :
1.3  ||| S:1749 E:1753 ||| CD
vs.  ||| S:1753 E:1757 ||| IN
1.9  ||| S:1757 E:1761 ||| CD
+ ||| S:1761 E:1762 ||| CD
/ ||| S:1762 E:1763 ||| CD
-  ||| S:1763 E:1765 ||| :
0.7  ||| S:1765 E:1769 ||| CD
mmol ||| S:1769 E:1773 ||| CD
/ ||| S:1773 E:1774 ||| CD
l ||| S:1774 E:1775 ||| NNS
;  ||| S:1775 E:1777 ||| :
P  ||| S:1777 E:1779 ||| NN
< ||| S:1779 E:1781 ||| SYM
0.05 ||| S:1781 E:1785 ||| CD
) ||| S:1785 E:1786 ||| -RRB-
.  ||| S:1786 E:1788 ||| .
In  ||| S:1788 E:1791 ||| IN
the  ||| S:1791 E:1795 ||| DT
control  ||| S:1795 E:1803 ||| NN
group ||| S:1803 E:1808 ||| NN
,  ||| S:1808 E:1810 ||| ,
base  ||| S:1810 E:1815 ||| NN
excess  ||| S:1815 E:1822 ||| NN
was  ||| S:1822 E:1826 ||| VBD
significantly  ||| S:1826 E:1840 ||| RB
corrected  ||| S:1840 E:1850 ||| VBN
at  ||| S:1850 E:1853 ||| IN
T1a ||| S:1853 E:1856 ||| NNP
,  ||| S:1856 E:1858 ||| ,
T1b ||| S:1858 E:1861 ||| NNP
,  ||| S:1861 E:1863 ||| ,
T1c ||| S:1863 E:1866 ||| NNP
,  ||| S:1866 E:1868 ||| ,
and  ||| S:1868 E:1872 ||| CC
T2  ||| S:1872 E:1875 ||| NNP
( ||| S:1875 E:1876 ||| -LRB-
P  ||| S:1876 E:1878 ||| NNP
< ||| S:1878 E:1880 ||| SYM
0.05 ||| S:1880 E:1884 ||| CD
) ||| S:1884 E:1885 ||| -RRB-
.  ||| S:1885 E:1887 ||| .
The  ||| S:1887 E:1891 ||| DT
SOFA  ||| S:1891 E:1896 ||| NNP
score  ||| S:1896 E:1902 ||| NN
was  ||| S:1902 E:1906 ||| VBD
significantly  ||| S:1906 E:1920 ||| RB
lower  ||| S:1920 E:1926 ||| JJR
in  ||| S:1926 E:1929 ||| IN
the  ||| S:1929 E:1933 ||| DT
rh-aPC  ||| S:1933 E:1940 ||| JJ
group  ||| S:1940 E:1946 ||| NN
compared  ||| S:1946 E:1955 ||| VBN
with  ||| S:1955 E:1960 ||| IN
the  ||| S:1960 E:1964 ||| DT
controls  ||| S:1964 E:1973 ||| NNS
at  ||| S:1973 E:1976 ||| IN
T2  ||| S:1976 E:1979 ||| NNP
( ||| S:1979 E:1980 ||| -LRB-
7.9  ||| S:1980 E:1984 ||| CD
+ ||| S:1984 E:1985 ||| CD
/ ||| S:1985 E:1986 ||| CD
-  ||| S:1986 E:1988 ||| :
2.2  ||| S:1988 E:1992 ||| CD
vs.  ||| S:1992 E:1996 ||| IN
12.2  ||| S:1996 E:2001 ||| CD
+ ||| S:2001 E:2002 ||| CD
/ ||| S:2002 E:2003 ||| CD
-  ||| S:2003 E:2005 ||| :
3.2 ||| S:2005 E:2008 ||| CD
;  ||| S:2008 E:2010 ||| :
P  ||| S:2010 E:2012 ||| NN
< ||| S:2012 E:2014 ||| SYM
0.05 ||| S:2014 E:2018 ||| CD
) ||| S:2018 E:2019 ||| -RRB-
.  ||| S:2019 E:2021 ||| .
There  ||| S:2021 E:2027 ||| EX
were  ||| S:2027 E:2032 ||| VBD
no  ||| S:2032 E:2035 ||| DT
differences  ||| S:2035 E:2047 ||| NNS
between  ||| S:2047 E:2055 ||| IN
groups  ||| S:2055 E:2062 ||| NNS
in  ||| S:2062 E:2065 ||| IN
StO2  ||| S:2065 E:2070 ||| CD
baseline ||| S:2070 E:2078 ||| NN
.  ||| S:2078 E:2080 ||| .
StO2  ||| S:2080 E:2085 ||| NNP
downslope  ||| S:2085 E:2095 ||| NN
in  ||| S:2095 E:2098 ||| IN
the  ||| S:2098 E:2102 ||| DT
rh-aPC  ||| S:2102 E:2109 ||| JJ
group  ||| S:2109 E:2115 ||| NN
decreased  ||| S:2115 E:2125 ||| VBD
significantly  ||| S:2125 E:2139 ||| RB
at  ||| S:2139 E:2142 ||| IN
all  ||| S:2142 E:2146 ||| PDT
the  ||| S:2146 E:2150 ||| DT
time  ||| S:2150 E:2155 ||| NN
points ||| S:2155 E:2161 ||| NNS
,  ||| S:2161 E:2163 ||| ,
and  ||| S:2163 E:2167 ||| CC
at  ||| S:2167 E:2170 ||| IN
T1b  ||| S:2170 E:2174 ||| NNP
and  ||| S:2174 E:2178 ||| CC
T2  ||| S:2178 E:2181 ||| NNP
( ||| S:2181 E:2182 ||| -LRB-
-16.5  ||| S:2182 E:2188 ||| NNP
+ ||| S:2188 E:2189 ||| NNP
/ ||| S:2189 E:2190 ||| NNP
-  ||| S:2190 E:2192 ||| :
11.8  ||| S:2192 E:2197 ||| CD
vs.  ||| S:2197 E:2201 ||| FW
-8.1  ||| S:2201 E:2206 ||| FW
+ ||| S:2206 E:2207 ||| FW
/ ||| S:2207 E:2208 ||| FW
-  ||| S:2208 E:2210 ||| :
2.4 ||| S:2210 E:2213 ||| CD
% ||| S:2213 E:2214 ||| NN
/ ||| S:2214 E:2215 ||| CD
minute ||| S:2215 E:2221 ||| NN
)  ||| S:2221 E:2223 ||| -RRB-
was  ||| S:2223 E:2227 ||| VBD
significantly  ||| S:2227 E:2241 ||| RB
steeper  ||| S:2241 E:2249 ||| JJR
than  ||| S:2249 E:2254 ||| IN
in  ||| S:2254 E:2257 ||| IN
the  ||| S:2257 E:2261 ||| DT
control  ||| S:2261 E:2269 ||| NN
group ||| S:2269 E:2274 ||| NN
.  ||| S:2274 E:2276 ||| .
StO2  ||| S:2276 E:2281 ||| NNP
upslope  ||| S:2281 E:2289 ||| VBD
increased  ||| S:2289 E:2299 ||| VBN
and  ||| S:2299 E:2303 ||| CC
was  ||| S:2303 E:2307 ||| VBD
higher  ||| S:2307 E:2314 ||| JJR
than  ||| S:2314 E:2319 ||| IN
in  ||| S:2319 E:2322 ||| IN
the  ||| S:2322 E:2326 ||| DT
control  ||| S:2326 E:2334 ||| NN
group  ||| S:2334 E:2340 ||| NN
at  ||| S:2340 E:2343 ||| IN
T1c ||| S:2343 E:2346 ||| NNP
,  ||| S:2346 E:2348 ||| ,
T1d  ||| S:2348 E:2352 ||| NNP
and  ||| S:2352 E:2356 ||| CC
T2  ||| S:2356 E:2359 ||| NNP
( ||| S:2359 E:2360 ||| -LRB-
101.1  ||| S:2360 E:2366 ||| NNP
+ ||| S:2366 E:2367 ||| NNP
/ ||| S:2367 E:2368 ||| NNP
-  ||| S:2368 E:2370 ||| :
62.1  ||| S:2370 E:2375 ||| FW
vs.  ||| S:2375 E:2379 ||| FW
54.5  ||| S:2379 E:2384 ||| FW
+ ||| S:2384 E:2385 ||| FW
/ ||| S:2385 E:2386 ||| FW
-  ||| S:2386 E:2388 ||| :
23.8 ||| S:2388 E:2392 ||| CD
% ||| S:2392 E:2393 ||| NN
/ ||| S:2393 E:2394 ||| CD
minute ||| S:2394 E:2400 ||| NN
)  ||| S:2400 E:2402 ||| -RRB-
( ||| S:2402 E:2403 ||| -LRB-
P  ||| S:2403 E:2405 ||| NNP
< ||| S:2405 E:2407 ||| SYM
0.05 ||| S:2407 E:2411 ||| CD
) ||| S:2411 E:2412 ||| -RRB-
.  ||| S:2412 E:2414 ||| .
Treatment  ||| S:2414 E:2424 ||| NN
with  ||| S:2424 E:2429 ||| IN
rh-aPC  ||| S:2429 E:2436 ||| NNP
may  ||| S:2436 E:2440 ||| MD
improve  ||| S:2440 E:2448 ||| VB
muscle  ||| S:2448 E:2455 ||| NN
oxygenation  ||| S:2455 E:2467 ||| NNS
( ||| S:2467 E:2468 ||| -LRB-
StO2  ||| S:2468 E:2473 ||| NNP
baseline ||| S:2473 E:2481 ||| NN
)  ||| S:2481 E:2483 ||| -RRB-
and  ||| S:2483 E:2487 ||| CC
reperfusion  ||| S:2487 E:2499 ||| NNS
( ||| S:2499 E:2500 ||| -LRB-
StO2  ||| S:2500 E:2505 ||| FW
upslope ||| S:2505 E:2512 ||| FW
)  ||| S:2512 E:2514 ||| -RRB-
and ||| S:2514 E:2517 ||| CC
,  ||| S:2517 E:2519 ||| ,
furthermore ||| S:2519 E:2530 ||| RB
,  ||| S:2530 E:2532 ||| ,
rh-aPC  ||| S:2532 E:2539 ||| JJ
treatment  ||| S:2539 E:2549 ||| NN
may  ||| S:2549 E:2553 ||| MD
increase  ||| S:2553 E:2562 ||| VB
tissue  ||| S:2562 E:2569 ||| NN
metabolism  ||| S:2569 E:2580 ||| NNS
( ||| S:2580 E:2581 ||| -LRB-
StO2  ||| S:2581 E:2586 ||| FW
downslope ||| S:2586 E:2595 ||| FW
) ||| S:2595 E:2596 ||| -RRB-
.  ||| S:2596 E:2598 ||| .
NIRS  ||| S:2598 E:2603 ||| NNP
is  ||| S:2603 E:2606 ||| VBZ
a  ||| S:2606 E:2608 ||| DT
simple ||| S:2608 E:2614 ||| JJ
,  ||| S:2614 E:2616 ||| ,
real-time ||| S:2616 E:2625 ||| JJ
,  ||| S:2625 E:2627 ||| ,
non-invasive  ||| S:2627 E:2640 ||| JJ
technique  ||| S:2640 E:2650 ||| NN
that  ||| S:2650 E:2655 ||| WDT
could  ||| S:2655 E:2661 ||| MD
be  ||| S:2661 E:2664 ||| VB
used  ||| S:2664 E:2669 ||| VBN
to  ||| S:2669 E:2672 ||| TO
monitor  ||| S:2672 E:2680 ||| VB
the  ||| S:2680 E:2684 ||| DT
effects  ||| S:2684 E:2692 ||| NNS
of  ||| S:2692 E:2695 ||| IN
rh-aPC  ||| S:2695 E:2702 ||| JJ
therapy  ||| S:2702 E:2710 ||| NN
at  ||| S:2710 E:2713 ||| IN
microcirculatory  ||| S:2713 E:2730 ||| JJ
level  ||| S:2730 E:2736 ||| NN
in  ||| S:2736 E:2739 ||| IN
septic  ||| S:2739 E:2746 ||| JJ
patients ||| S:2746 E:2754 ||| NNS
.  ||| S:2754 E:2756 ||| .
